Teva Zecuity's Safety: Burns Go From Non-Issue In Label To Product Puller
This article was originally published in The Pink Sheet Daily
Executive Summary
Fate of migraine patch remains uncertian after 'large number' of patients suffer burns and scars; adverse event was issue during review of transdermal sumatriptan product, but didn't even make it into labeling; nine months later the problems have forced Teva to suspend marketing.
You may also be interested in...
Leaking Heat Cells In Pfizer's ThermaCare HeatWraps Prompt Recall
Firm's consumer health division extends to consumer level a recall it advised retailers and distributors about on Oct. 2 because products from the six lots have a potential to leak ingredients contained in heat cell wraps. A leaking heat cell in a HeatWrap could cause skin injuries such as burns, blisters or skin irritation on the applied areas.
Leaking Heat Cells In Pfizer's ThermaCare HeatWraps Prompt Recall
Firm's consumer health division extends to consumer level a recall it advised retailers and distributors about on Oct. 2 because products from the six lots have a potential to leak ingredients contained in heat cell wraps. A leaking heat cell in a HeatWrap could cause skin injuries such as burns, blisters or skin irritation on the applied areas.
Zecuity Redesign Got Migraine Patch Through FDA, But Burning Continued
FDA worries about burning and scarring with the battery-powered Zecuity patch prompted NuPathe to reconfigure the drug-device combo; our Drug Review Profile shows how FDA thought the problem was solved, but adverse reaction reports soon after launch led to marketing suspension.